Corridor Pharmaceuticals

About:

Corridor Pharmaceuticals is a platform-based pulmonary and critical care company developing novel therapeutics for elevated arginase levels.

Website: http://www.corridorpharma.com

Top Investors: NewSpring, Ben Franklin Technology Partners of Southeastern Pennsylvania, OUP (Osage University Partners), Domain Associates, Quaker BioVentures

Description:

Corridor Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutic small molecule inhibitors of arginase. Its arginase is an enzyme that competes with endothelial nitric oxide synthase for the use of the common substrate l-arginine. The company's arginase also leads to the production of ornithine which increases polyamine, stimulating cell division, and contributing to hyperplasia and fibrosis. Corridor Pharmaceuticals, Inc. was formerly known as Arginetix, Inc. and changed its name to Corridor Pharmaceuticals, Inc. on June 17, 2010. The company was founded in 2007 and is based in Lutherville, Maryland.